Imatinib does not induce cardiac left ventricular failure in gastrointestinal stromal tumours patients: Analyis of EORTC-ISG-AGITG study 62005

Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia

“…27 A similar review has been performed in 972 patients with metastatic/inoperable gastrointestinal stromal tumor reported from an EORTC-ISG-AGITG study 62005 in which 7 patients were felt to have suffered a cardiac failure, including one death. 23 An in-depth analysis of these cases identified cardiac risk factors in each patient, leading the authors to conclude that imatinib does not induce cardiac left ventricular failure in inoperable gastrointestinal stromal tumor patients.…”

“…19 Two recent publications have addressed this concern in large numbers of patients. 23,24 The first report by Atallah et al 24 reviewed the records of 1276 patients who received imatinib on clinical trails at the MD Anderson Cancer Center. In total, 22 (1.7%) of these patients were identified as having symptoms that could be related to CHF, although only 8 (0.6%) of these were considered possibly or probably related to imatinib.…”

2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines

“…Mimo że wstępne doniesienia wskazywały na ryzyko kardiotoksyczności wywoływanej przez imatinib, analiza dużych grup nie potwierdziła tych danych [73]. Związek z incydentami CV stwierdzono również w przypadku nowszych, silniejszych inhibitorów kinazy BCR-ABL, takich jak nilotinib i ponatinib [74,75].…”

Cardiotoxicity induced by tyrosine kinase inhibitors

“…Another recent study disputed the possibility of cardiotoxicity from imatinib by measuring the BNP levels and finding no evidence of cardiotoxicity of imatinib therapy [11]. Similarly, in the largest study performed so far, in 946 patients with GIST, in all but two patients a possible cardiotoxic effect of imatinib could be fully excluded [12]. Cardiovascular assessment was based on physical examination and chest x-ray only, which by no means can be considered optimal for cardiovascular risk evaluation.…”